 |
|
|||||||||||||||||||||||||||||||||
| [發(fā)表評論] [本類其他產(chǎn)品] [本類其他供應商] [收藏] | ||||||||||||||||||||||||||||||||||
| 銷售商： 上海皓元生物醫(yī)藥科技有限公司 | 查看該公司所有產(chǎn)品 >> |
MCE 的所有產(chǎn)品僅用作科學研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務。
EtodolacCAS No. : 41340-25-4
MCE 國際站：Etodolac
產(chǎn)品活性：Etodolac (AY-24236) 是非甾體抗炎化合物，對 COX 的 IC50為53.5 nM。
作用靶點：COX
In Vitro: Post-marketing studies demonstrated that etodolac inhibition of cyclooxygenase is somewhat COX-2 selective similar to celecoxib and other "COX-2 inhibitors." Unlike rofecoxib, both etodolac and celecoxib can fully inhibit COX-1 and are designated as having "preferential selectivity" toward COX-2. The (inactive against COX) r-enantiomer of etodolac inhibits beta-catenin levels in hepatoma cells.
相關產(chǎn)品：Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Immunology/Inflammation Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | CNS-Penetrant Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Anti-COVID-19 Compound Library | NMPA-Approved Drug Library | Pyroptosis Compound Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Drug-Induced Liver Injury (DILI) Compound Library | Anti-Pancreatic Cancer Compound Library | Acetaminophen | Indomethacin | Celecoxib | Aspirin | Ibuprofen | Catechin | NS-398 | 20(S)-Ginsenoside Rg3 | Naproxen | Diclofenac Sodium | Sulindac | (-)-Epicatechin | SC-560 | Gallic acid | Carprofen | Salicylic acid | Xanthohumol | Rutaecarpine | Meloxicam | Rebamipide | Iguratimod | Rofecoxib | Neochlorogenic acid | Fenofibric acid | Nabumetone | Piroxicam | Flufenamic acid
品牌介紹:
• MCE (MedChemExpress) 擁有數(shù)百種全球獨家化合物，我們致力于為全球科研客戶提供最新最全的高品質(zhì)小分子活性化合物；
• 10,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領域；
• 設有專業(yè)的實驗中心和嚴格的質(zhì)控、驗證體系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質(zhì)檢報告，確保產(chǎn)品的高純度、高品質(zhì)；
• 產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證；
• Nature, Cell, Science 等多種頂級期刊及制藥專利收錄了MCE客戶的科研成果；
• 專業(yè)團隊跟蹤最新的制藥及生命科學研究進展，為您提供全球最新的活性化合物；
• 與世界各大制藥公司及知名科研機構建立了長期的合作。
